ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,249Medicare Part D Prescriptions Filled, Including Refills

Rank: 113 out of 252

$501K Total Retail Price of All Prescriptions

Rank: 98 out of 252

336 Patients Receiving at Least One Drug in Part D
73%Patients 65 Years and Older
54% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 336 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

14% of this provider’s 336 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 6,039 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

32% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
LISINOPRIL 337 260 1 3
OMEPRAZOLE 298 215 2 6
AMLODIPINE BESYLATE 285 238 3 4
CRESTOR 253 208 4 34
LEVOTHYROXINE SODIUM 250 199 5 1
METFORMIN HCL 249 190 6 9
CARVEDILOL 231 194 7 22
SIMVASTATIN 216 182 8 2
TRAMADOL HCL 201 101 9 17
HYDROCODONE-ACETAMINOPHEN 187 109 S3 10 5
FUROSEMIDE 161 147 11 7
ZOLPIDEM TARTRATE 140 100 12 21
DIOVAN 128 105 13 38
WARFARIN SODIUM 127 115 14 14
NIASPAN 123 94 15 167
SYNTHROID 111 71 16 47
CITALOPRAM HBR 90 53 17 15
METOPROLOL TARTRATE 90 74 17 10
HYDROCHLOROTHIAZIDE 90 67 17 13
GABAPENTIN 86 66 20 11
ATORVASTATIN CALCIUM 85 63 21 16
EXFORGE 83 83 22 169
MIRTAZAPINE 81 48 23 58
MELOXICAM 80 59 24 20
CLONIDINE HCL 80 61 24 35
ATENOLOL 73 46 26 18
PANTOPRAZOLE SODIUM 72 54 27 62
BENAZEPRIL HCL 71 49 28 80
NEXIUM 71 40 28 23
DIOVAN HCT 70 70 30 65
PREDNISONE 69 60 31 42
PRAVASTATIN SODIUM 68 58 32 12
FENOFIBRATE 61 40 33 64
POTASSIUM CHLORIDE 60 57 34 8
ENALAPRIL MALEATE 60 39 34 72
LISINOPRIL-HYDROCHLOROTHIAZIDE 60 28 34 25
LYRICA 59 20 37 66
LOSARTAN POTASSIUM 59 40 37 24
ADVAIR DISKUS 58 43 39 63
KLOR-CON 10 56 49 40 146
TAMSULOSIN HCL 54 43 41 26
TRAZODONE HCL 53 13 42 31
CYMBALTA 52 28 43 45
ALENDRONATE SODIUM 51 51 44 32
ALLOPURINOL 51 47 44 30
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 18, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.